Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor (venlafaxine hydrochloride) for the treatment of adults with generalized anxiety disorder (GAD), Viatris Inc. announced on March 23, 2026. The decision makes Effexor the first and only approved pharmacological treatment for GAD in Japan, a market where no drug had previously carried this specific indication despite the condition affecting an estimated 7.6% of the general population. Venlafaxine, a serotonin-noradrenaline reuptake inhibitor (SNRI) originally developed by Wyeth and later acquired by Pfizer before passing to Viatris through the 2020 Upjohn spin-off, has been approved for GAD in more than 80 countries. Effexor was already approved in Japan for major depressive disorder in adults; this supplemental approval extends its label to a second indication in the same market.
The MHLW granted approval for Effexor SR 37.5 mg and 75 mg capsules. The company said the decision addresses a long-standing regulatory gap in Japan, where clinicians have historically managed GAD patients using off-label antidepressants and benzodiazepines in the absence of a formally indicated therapy. The World Health Organization estimates a 2.6% lifetime prevalence of GAD in Japan, though a 2024 population survey by Matsuyama et al. reported a probable prevalence of 7.6%, suggesting the condition is underdiagnosed.
The approval was supported by a Phase III placebo-controlled, randomized, double-blind, multicenter study (B2411367) conducted in Japanese adults with GAD. The trial met its primary endpoint, demonstrating superiority of venlafaxine over placebo at eight weeks as measured by change from baseline in the Hamilton Anxiety Rating Scale (HAM-A) total score (two-sided p-value = 0.012). All seven protocol-defined secondary efficacy endpoints were also met, the company said. Discontinuation rates due to treatment-emergent adverse events were 7.3% in the venlafaxine arm versus 1.7% for placebo, with 3.9% versus 0.6% assessed as treatment-related. No serious treatment-emergent adverse events or events of severe intensity were observed in the venlafaxine group. Results from a long-term extension study in Japanese outpatients with GAD were also included in the regulatory submission, which Viatris filed with the MHLW in April 2025.
The approval fills a specific gap in the Japanese treatment landscape but arrives in a broader global context where GAD pharmacotherapy has seen little innovation. No novel-mechanism drugs have been approved for GAD by the US FDA, EMA, or MHLW in the past five years. The established standard of care internationally relies on SSRIs such as escitalopram and sertraline, SNRIs including venlafaxine and duloxetine, and second-line agents such as buspirone and pregabalin, the latter approved for GAD in the EU but not in the United States. Several investigational agents targeting glutamatergic, GABAergic, and serotonergic psychedelic pathways are in clinical development, but none have yet reached regulatory approval for this indication. For Viatris, the approval adds to a growing portfolio of central nervous system therapies in Japan and reflects the company's lifecycle management strategy for established brands inherited from the Pfizer Upjohn transaction.
Spot something wrong? Report an issue with this article